$SEER

Seer, Inc. (SEER): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Seer, Inc. (SEER) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 14, 2026, David Horn resigned as the President, Chief Financial Officer and Treasurer of Seer, Inc. (the “Comp

Original reporting
Published Sep 18, 2026, 8:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 8:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$SEER
Neutral
medium confidence
Mentioned
$SEER
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$SEERNeutralLow
01

Why it matters

The change in top financial leadership may influence short‑term trading sentiment but lacks immediate financial metrics.

02

Market read

Primary disclosure of executive turnover; modest trading relevance for SEER.

03

What to watch

Potential hidden succession planning or strategic shifts not disclosed in the filing.

Relevance 6/10Novelty 6/10Timing: effective Oct 1, 2026

Background

Seer, Inc. filed an 8‑K reporting executive departures and new appointments, a routine corporate governance disclosure.

Company-level read

Ticker impact

$SEERNeutralMedium confidence
Context

SEC Form 8‑K discloses the resignation of President/CFO David Horn and appointment of Omid Farokhzad as President and Charles Endweiss as Treasurer, effective Oct 1, 2026.

Expected impact

Potential modest downside or sideways movement until market digests the new appointments.

Evidence & confidence

Executive turnover is material but no immediate financial impact is disclosed; market reaction typically hinges on perceived continuity.

Market effects

Minimal; leadership change is specific to Seer and does not signal broader sector trends.

None; the filing is company‑specific and does not affect regional markets.

Low; no global macro or cross‑border implications.

Counterpoint

The appointment of the existing CEO as President could be seen as a vote of confidence, limiting downside risk.

Key entities

  • David Horn

    Resigned as President, CFO, and Treasurer effective Oct 1, 2026.

  • Omid Farokhzad, M.D.

    Appointed President while retaining CEO and Board Chair roles.

  • Charles Endweiss

    Appointed Treasurer and principal financial/accounting officer.

Related articles

$SEERMedAI 8/10

Seer Inc. Q2 2026 Earnings: Revenue Misses $3.1 Million

Seer Inc. (Nasdaq: SEER) reported Q2 2026 revenue of $3.1 million, below consensus of $4.0 million, and a net loss of $0.31 per share versus a $0.22 loss expected. The company reaffirmed full-year 2026 revenue guidance of $16 million to $18 million. Shares fell about 2.78% after hours to $2.10.

$SEERMedAI 8/10

Seer Reports Second Quarter 2026 Financial Results

Seer, Inc. (SEER) filed an SEC Form 8-K — Results of Operations and Financial Condition. Seer Reports Second Quarter 2026 Financial Results and Reaffirms Full Year 2026 Outlook REDWOOD CITY, Calif. – August 11, 2026 – Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced financial r

$SEERMedAI 8/10

Two Revised, Non-Binding Proposals Seek to Acquire All of Seer's Class A Shares

Seer Confirms Receipt of Further Revised Unsolicited Acquisition Proposals From Radoff-JEC Group and From Omid Farokhzad, M.D. Rhea-AI Summary Seer (Nasdaq: SEER) confirmed receipt of two further revised, unsolicited, non-binding acquisition proposals for all outstanding shares of its Class A common stock. On July 28, 2026, the Radoff-JEC Group offered $2.55 per share in cash plus a contingent value right.

$LUCYMedAI 8/10

Top Biotech Gainers: LUCY Shines, SEER Gets Takeover Offer, OFIX, ENOV Rally On CMS Update

Biotech gainers: Innovative Eyewear (LUCY) rose 63% after preliminary Q2 2026 net sales of ~$0.99M (+71% YoY) and new retail orders; Seer (SEER) jumped 35% on an unsolicited $2.45/share cash takeover proposal plus contingent value rights; Orthofix (OFIX) and Enovis (ENOV) gained 16%/15% after CMS withdrew reimbursement changes for non-invasive bone growth stimulators.